目的 探討丙卡特羅聯(lián)合多索茶堿治療支氣管哮喘急性發(fā)作期的臨床療效。方法 選取2021年8月—2023年8月呼吸科收治的支氣管哮喘急性發(fā)作期患者128例，隨機(jī)分為對(duì)照組（64例）和治療組（64例）。對(duì)照組患者靜脈滴注多索茶堿注射液，300 mg加入生理鹽水100 mL，1次/d。在對(duì)照組的基礎(chǔ)上，治療組口服鹽酸丙卡特羅顆粒，50 μg/次，3次/d；兩組治療10 d。觀察兩組患者臨床療效，比較治療前后兩組患者臨床癥狀恢復(fù)時(shí)間，哮喘控制測(cè)試量表（ACT）評(píng)分，血清半胱氨酰白三烯（Cys-LTs）、嗜酸性粒細(xì)胞趨化因子（Eotaxin）、白細(xì)胞介素-6（IL-6）和血小板衍生生長(zhǎng)因子（PDGF-BB）水平。結(jié)果 治療后，治療組臨床總有效率為98.44%，明顯高于對(duì)照組總有效率（84.38%，P＜0.05）。治療后，治療組癥狀恢復(fù)時(shí)間均明顯早于對(duì)照組（P＜0.05）。治療后，兩組患者ACT評(píng)分比治療前明顯升高（P＜0.05），且治療組患者ACT評(píng)分明顯高于對(duì)照組（P＜0.05）。治療后，兩組患者血清Cys-LTs、Eotaxin、IL-6、PDGF-BB水平比治療前明顯降低（P＜0.05），且治療組水平均明顯低于對(duì)照組（P＜0.05）。結(jié)論 丙卡特羅與多索茶堿協(xié)同治療，可有效改善哮喘發(fā)作期癥狀，增強(qiáng)哮喘控制能力，降低局部炎性因子含量。

Objective To explore the clinical effect of doxophylline combined with procaterol in treatment of acute attack of bronchial asthma. Methods Patients (128 cases) with acute attack of bronchial asthma in Henan Province Chest Hospital from August 2021 to August 2023 were randomly divided into control (64 cases) and treatment (64 cases) group. Patients in the control group were iv administered with Doxofylline Injection, 300 mg added into normal saline 100 mL, once daily. Patients in the treatment group were po administered with Procaterol Hydrochloride Granules on the basis of the control group, 50µg/time, three times daily. Patients in two groups were treated for 10 d. After treatment, the clinical evaluations were evaluated, the symptom relief time, ACT scores, the levels of serum Cys-LTs, Eotaxin, IL-6 and PDGF-BB in two groups before and after treatment were compared. Results After treatment, the clinical effective rate of the treatment group was 98.44%, which was significantly higher than that of the control group (84.38%, P < 0.05). After treatment, the recovery time of symptoms in the treatment group was significantly earlier than that in the control group (P < 0.05). After treatment, the ACT score in two groups was significantly higher than that before treatment (P < 0.05), and the ACT score in the treatment group was significantly higher than that of the control group (P < 0.05). After treatment, the serum levels of Cys-LTs, Eotaxin, IL-6 and PDGF-BB in two groups were significantly lower than those before treatment (P < 0.05), and the levels in the treatment group were significantly lower than those in the control group (P< 0.05). Conclusion The combined treatment of procaterol and doxophylline can effectively improve the symptoms of asthma attack, enhance the ability of asthma control and reduce the content of local inflammatory factors.

R974